STOCK TITAN
  1. Home
  2. Sec-filings
  3. CPRX
  4. [Form 4] CATALYST PHARMACEUTICALS, INC. Insider Trading Activity

Catalyst Pharma (CPRX) director equity grants and RSU vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Catalyst Pharmaceuticals, Inc. (CPRX) director David S. Tierney reported equity awards and a share delivery around late November 2025. On 11/20/2025, he was granted options to purchase 18,115 shares of common stock at an exercise price of $22.77 per share, vesting in three equal annual installments on November 20, 2026, 2027, and 2028. He was also granted 5,468 restricted stock units (RSUs), which convert into the same number of common shares upon vesting on the same three-year schedule.

On 11/21/2025, 947 RSUs were settled into common stock, adding 947 shares of common stock to his direct holdings and reducing his derivative balance. After these transactions, he directly owned 380,567 shares of common stock and held 180,910 derivative securities, including options and RSUs, all reported as directly owned.

Positive

  • None.

Negative

  • None.
Insider Tierney David S
Role Director
Type Security Shares Price Value
Exercise Restricted Stock Units 947 $0.00 --
Exercise Common Stock, par value $0.001 per share 947 $0.00 --
Grant/Award Options to purchase common stock 18,115 $0.00 --
Grant/Award Restricted Stock Units 5,468 $0.00 --
Holdings After Transaction: Restricted Stock Units — 180,910 shares (Direct); Common Stock, par value $0.001 per share — 380,567 shares (Direct); Options to purchase common stock — 176,389 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028. Shares of common stock will be delivered to the Reporting Person upon vesting. Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tierney David S
(Last) (First) (Middle)
355 ALHAMBRA CIRCLE, SUITE 801
(Street)
CORAL GABLES FL 33134
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CATALYST PHARMACEUTICALS, INC. [ CPRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.001 per share 11/21/2025 M 947 A (1) 380,567 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options to purchase common stock $22.77 11/20/2025 A 18,115 (2) 11/20/2032 Common Stock 18,115 $0 176,389 D
Restricted Stock Units (3) 11/20/2025 A 5,468 (2) (3) Common Stock 5,468 $0 181,857 D
Restricted Stock Units (3) 11/21/2025 M 947 (4) (5) Common Stock 947 $0 180,910 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
2. Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028.
3. Shares of common stock will be delivered to the Reporting Person upon vesting.
4. Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.
5. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.
/s/ David S. Tierney 11/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did CPRX director David S. Tierney report in this Form 4?

David S. Tierney, a director of Catalyst Pharmaceuticals, Inc. (CPRX), reported new option and RSU grants on November 20, 2025, and the delivery of shares from vested RSUs on November 21, 2025. These transactions update his ownership of CPRX common stock and derivative securities.

How many CPRX stock options were granted and at what exercise price?

Tierney received options to purchase 18,115 shares of CPRX common stock at an exercise price of $22.77 per share. These options were granted on 11/20/2025 and vest in three equal installments on November 20, 2026, 2027, and 2028.

How many restricted stock units (RSUs) of CPRX were granted?

On 11/20/2025, Tierney was granted 5,468 restricted stock units. Each RSU represents a right to receive one share of CPRX common stock upon vesting, in three equal tranches on November 20, 2026, November 20, 2027, and November 20, 2028.

What happened with the 947 restricted stock units on 11/21/2025?

On 11/21/2025, 947 RSUs vested and were settled into 947 shares of CPRX common stock. Those shares were delivered to Tierney and increased his directly held common stock, while the corresponding RSUs were removed from his derivative holdings.

What are David S. Tierney’s CPRX common stock holdings after these transactions?

Following the reported transactions, Tierney directly owned 380,567 shares of CPRX common stock. This figure reflects the addition of 947 shares delivered upon RSU vesting on November 21, 2025.

How many CPRX derivative securities does the director hold after the Form 4 transactions?

After the option and RSU grants and the RSU settlement, Tierney held 180,910 derivative securities of CPRX. This total includes stock options and restricted stock units that were reported as directly owned.

How do the CPRX equity awards reported here vest over time?

The options and the 5,468 RSUs granted on 11/20/2025 vest in three equal tranches: 1/3 on November 20, 2026, 1/3 on November 20, 2027, and 1/3 on November 20, 2028. For a separate RSU grant referenced in the explanations, shares vest in equal tranches on November 21, 2025, 2026, and 2027, with shares required to be delivered within sixty days of vesting.